ZVRA

Zevra Therapeutics, Inc. (ZVRA) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Zevra Therapeutics is a commercial-stage biopharmaceutical company focused on rare diseases. Key commercial assets include MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company also holds a pipeline of investigational candidates, including celiprolol for Vascular Ehlers-Danlos syndrome (VEDS) and KP1077 for idiopathic hypersomnia.

Key Financial Metrics

Note: Cash and investments figure is the sum of Cash ($47.7M) and Securities ($170.0M) as of June 30, 2025.

Material Changes vs. Prior Period

• Net Income Surge: The company reported a net income of $74.7 million for Q2 2025, a reversal from a $19.9 million loss in Q2 2024. This is primarily driven by a one-time gain on the sale of a Priority Review Voucher (PRV) of $148.3 million.
• Revenue Growth: Net revenue increased 482% year-over-year to $25.9 million, driven by $21.5 million in sales of MIPLYFFA following its FDA approval in September 2024.
• Significant Impairment: The company recorded a non-cash impairment charge of $58.7 million related to the OLPRUVA intangible asset group due to refined commercial assessments indicating lower future cash flows.
• Inventory Obsolescence: Cost of product revenue included an $11.7 million charge for unsaleable inventory write-downs, compared to $3.2 million in the prior year.
• Expense Management: Research and development expenses decreased by 68% ($7.1 million) due to reduced spending on the KP1077 Phase 2 study and personnel costs. Conversely, Selling, General, and Administrative (SG&A) expenses increased by 65% ($8.2 million) to support commercialization efforts.

Guidance, Outlook, and Risks

• Liquidity: As of June 30, 2025, the company held approximately $217.7 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least the next 12 months.
• Commercial Outlook: MIPLYFFA is commercially available in the U.S. and has received orphan designation in Europe, with a Marketing Authorization Application (MAA) submitted in July 2025. The company is actively recruiting for the Phase 3 DiSCOVER trial for celiprolol (VEDS).
• Legal Contingency: The company is engaged in litigation with Commave Therapeutics regarding the interpretation of the AZSTARYS License Agreement. The case is in the discovery phase, and while no accrual has been made, significant legal expenses are expected.
• Regulatory Risks: The filing highlights risks related to the "One Big Beautiful Bill Act" (signed July 2025) reducing Medicaid funding, which could impact sales of MIPLYFFA and OLPRUVA. Additionally, the company faces potential pricing pressures from the Inflation Reduction Act.

Investor Verification Checklist

• PRV Sale Proceeds: Verify the receipt of the $148.3 million net proceeds from the PRV sale and confirm the cash balance on the balance sheet.
• OLPRUVA Impairment: Review the assumptions used in the fair value measurement for the $58.7 million impairment charge to understand the revised commercial outlook for this asset.
• Inventory Write-downs: Investigate the cause of the $11.7 million inventory obsolescence charge and its impact on future cost of goods sold.
• Debt Covenants: Confirm compliance with the $20 million minimum cash balance covenant and minimum net product sales requirements under the $100 million Term Loan facility.
• Litigation Status: Monitor the progress of the AZSTARYS License Agreement dispute with Commave for potential impacts on royalty revenue.